HHS 503A peptide notice: what the docket and our price data show
The Pep Chart, November 13, 2026. Facts only, each with its source. Information only, not medical advice.
In three lines
- HHS names six peptides it will not act against when a state-licensed pharmacy compounds them under its conditions: BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax. It is not FDA approval.
- 115 public comments had been posted on docket HHS-OASH-2026-0496 by November 13, 2026, the first on November 3, 2026. Comment deadline: November 13, 2026, 11:59 pm Eastern.
- None of the six is sold by any program on The Pep Chart, so the notice changes no price we list.
The public comments
Regulations.gov showed 115 comments posted on docket HHS-OASH-2026-0496 when we read it on November 13, 2026. The site posts a comment after HHS reviews it, so the count can trail what has been sent. The docket itself lists the notice and a copy of the policy, both posted October 30, 2026. Read the comments on regulations.gov, or our saved copy of the count.
What it means for prices on our chart
No program on The Pep Chart sells any of the six peptides the notice names. The 3 it leaves out, GHK-Cu, CJC-1295 and Ipamorelin, are not on our chart either. The prices we track are for products the notice does not name, so it does not touch them. Those prices are in our monthly price index, with a CSV.
What to watch
- Comment deadline: November 13, 2026, 11:59 pm Eastern. HHS can revise the policy after it reads them.
- The notice says the policy is interim, while the FDA works through rulemaking on the 503A bulks list.
- The notice says HHS may revisit the policy if a safety signal or a product quality problem arises.
What the policy says, line by line, is in our HHS 503A peptide policy explainer. To check a seller before you pay, use the peptide seller checklist.
Sources
- HHS notice in the Federal Register, 91 FR 68526, published October 30, 2026.
- Regulations.gov, docket HHS-OASH-2026-0496, comments, read November 13, 2026.
Reporters: quote any line with a credit link. Data and contact are on the press page.
Cite this page
Permalink: https://thepepchart.com/fda-peptide-rules/hhs-503a-peptide-policy/commentary/
Suggested citation: The Pep Chart. "HHS 503A peptide notice: what the docket and our price data show." November 13, 2026. https://thepepchart.com/fda-peptide-rules/hhs-503a-peptide-policy/commentary/
Free to quote and chart with a credit link. The terms are on reuse our data, and reporters can start on the press page.